# Dren Bio

Source: https://onco.cc/companies/dren-bio/  
OnCo record `dren-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Dren Bio is a Californian biotech whose bispecific antibodies recruit macrophages to engulf diseased cells; DR-01 directs this against CD94 to clear the cancerous cells of T-cell and natural killer cell lymphomas.

## Summary

Dren Bio develops targeted myeloid engagers, bispecific antibodies that bind a disease antigen on one arm and a phagocytic receptor on macrophages with the other, so the target cell is engulfed. DR-01, its first clinical programme, depletes CD94-expressing cytotoxic lymphocytes and is in a phase 1/2 study in large granular lymphocytic leukaemia and cytotoxic lymphomas. Its CD20-directed engager DR-0201 for autoimmune disease was licensed to Sanofi in 2025.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Dren Bio, Inc.
- Tags: drug-maker
- HQ: Foster City, California
- Type: biotech
- Website: https://www.drenbio.com/

## Sources

- Official website: https://www.drenbio.com/

## Connected records

- drugs: [DR-01](https://onco.cc/drugs/dr-01/)

---
JSON: https://onco.cc/api/v1/entities/dren-bio.json